Lessons from RUTH

Climacteric

Volumn 9, Issue 5, 2006, Pages 323-324

  Pines, Amos ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

AGING; BREAST CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FOLLOW UP; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

BREAST NEOPLASMS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; POSTMENOPAUSE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SPINAL FRACTURES; THROMBOEMBOLISM;

EID: 33749036845     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600963272     Document Type: Review

References (6)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
2. Barrett-Connor E, Ensrud KE, Harper K, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003;25:919-30
3. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA 2002;287:847-57
4. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
5. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene P-2 trial. JAMA 2006;295:2727-41
6. Melnikow J, Kuenneth C, Helms LJ, et al. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer 2006;107:950-8